Plain-English translation of NCT06572462 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a more personalized approach to dosing Thymoglobulin (a medicine that suppresses the immune system) can improve results in patients receiving stem cell transplants from unrelated donors. Thymoglobulin is routinely used during transplant to prevent a serious complication called graft-versus-host disease. This trial uses blood tests to measure how much of the medication is actually active in your body, then adjusts your doses to keep the level in an optimal range—potentially reducing infections and other complications.
Currently, doctors give all patients the same fixed dose of this medication, but research suggests that different patients need different amounts to get the best results. Too much medication can increase infection risk, while too little may not prevent complications effectively. This trial aims to find the 'just right' dose for each individual patient using personalized measurements.
You likely qualify if…
You likely don't qualify if…
You will receive a stem cell transplant with a special conditioning regimen that includes the study medication. Your doses will be personalized: you'll receive standard doses on days −5 and −4, then your doses on days −3 and −2 will be adjusted based on blood measurements taken on days −5 and −4 to ensure your medication level stays in the optimal range. You'll have regular blood tests and clinical monitoring throughout the transplant process and recovery period to track your response and watch for any complications.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
China